Tivic Health accelerates development of VNS commercial strategy Page 1

Tivic Health Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health technology company developing and commercializing bioelectronic medicine, today announced that it has entered into a partnership with Fletcher Spaght (“FSI”), a leading healthcare growth strategy company, to accelerate the development of its commercial strategy for non-invasive cervical vagus nerve stimulation (“ncVNS”).

Polaris Market Research estimates that the global vagus nerve stimulation market will grow from $8.59 billion in 2021 to $21.3 billion by 2030, a CAGR of 10.6% over the forecast period. In addition, IDTechEx has predicted that peripheral nerve stimulation, the segment targeted by Tivic Health, will grow at a CAGR of 35%, one of the fastest growing segments in bioelectronic medicine.